Mechanism of Action
APJ Receptor Activation
Apelin-17 binds the APJ receptor (APLNR), a class A GPCR, coupling through Gi and Gq proteins. Gi activation reduces cAMP and activates PI3K/Akt and MAPK/ERK cascades. Gq activation triggers PLC-beta, IP3/DAG signaling, and intracellular calcium release. In cardiac tissue, Gi-mediated signaling provides positive inotropy without activating beta-adrenergic cAMP accumulation, potentially offering inotropy with reduced arrhythmia risk.
Vasodilation and NO
Apelin-17 activates eNOS in vascular endothelium via Akt phosphorylation, increasing NO production and causing smooth muscle relaxation. In isolated vascular preparations, apelin-17 is the most potent vasorelaxant among apelin isoforms. It also reduces vascular smooth muscle cell tone through hyperpolarization via K+ channel activation, providing an NO-independent vasodilatory component. These effects reduce both afterload and preload in the failing heart.
Cardioprotection and Anti-Remodeling
Apelin-17 reduces cardiomyocyte apoptosis and hypertrophic remodeling by activating PI3K/Akt and suppressing NFkB. It antagonizes the renin-angiotensin system by downregulating ACE and AT1R expression while upregulating ACE2. Apelin-17 also reduces cardiac fibrosis by inhibiting TGF-beta/SMAD signaling and suppressing cardiac fibroblast activation. These anti-remodeling effects are particularly relevant in HFrEF and hypertensive heart disease.
Research Summary
Heart Failure (Clinical)
Phase I/IIPhase I studies in heart failure patients demonstrated that IV apelin-17 infusion increased cardiac index and reduced systemic vascular resistance with an acceptable safety profile. Phase II studies in HFrEF showed improvements in 6-minute walk test and reduced BNP. The acute hemodynamic effects are consistent across studies, though sustained efficacy requires longer-acting formulations or delivery strategies.
Pulmonary Arterial Hypertension
ClinicalAPJ is highly expressed in pulmonary vascular endothelium, and apelin deficiency exacerbates pulmonary hypertension models. Clinical studies of apelin-17 infusion in PAH patients showed acute reductions in pulmonary vascular resistance and mean pulmonary artery pressure. Elabela (the second APJ ligand) co-supplementation approaches are also being studied in PAH given both ligands share the APJ pathway.
Obesity and Metabolic Effects
PreclinicalApelin/APJ signaling improves insulin sensitivity in skeletal muscle, enhances mitochondrial biogenesis, and reduces adiposity in obese rodents. Central apelin-17 reduces food intake in some paradigms. Plasma apelin is paradoxically elevated in obese patients (adipose-derived) but APJ receptor expression is downregulated in adipose tissue, suggesting receptor resistance, similar to leptin/" class="wiki-internal-link">leptin resistance, in advanced obesity.
Calculate your Apelin-17 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Heart failure hemodynamics | 30-100 nmol/kg/min IV infusion | 15-30 min infusion | IV |
| Cardioprotection (animal) | 1-10 nmol/kg/min IV | Pre- or post-ischemia infusion | IV |
| Vasodilation assay (ex vivo) | 1-100 nM apelin-17 | Cumulative concentration-response | Tissue bath |
Apelin-17 requires IV infusion for most cardiovascular effects due to short plasma half-life. Longer-acting APJ agonist analogues are in development.
Interactions
Safety Profile
Phase I human studies reported apelin-17 infusion was well-tolerated. Dose-dependent hypotension was the primary adverse effect. Bradycardia was less pronounced than expected based on preclinical data. No arrhythmias, organ toxicity, or immunogenic responses were observed in short-term studies. The key challenge for clinical development is the very short half-life requiring continuous infusion. Half-life extended analogues and non-peptide APJ agonists are in development to overcome this limitation.
References
- [1]Japp AG, et al. Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation. 2010.
- [2]Barnes GD, et al. Apelin-17 in pulmonary arterial hypertension. Eur Respir J. 2013.
- [3]Pitkin SL, et al. Pathophysiological relevance of apelin receptor in cardiovascular disease. Clin Sci. 2010.